Hepatitis
From the Journals
Hepatitis Outlook: January 2017
Strong evidence exists that Western health professionals miss opportunities for hepatitis B virus testing and vaccination of Chinese migrant...
Conference Coverage
ACR guidelines on HBV screening called inadequate
SNOWMASS, COLO. The selective screening of patients for HBV in the 2015 ACR guidelines for treatment of rheumatoid arthritis should be skipped in...
From the Journals
Eradicate HCV in patients with HIV, regardless of fibrosis stage
Eradicating hepatitis C virus in HIV-coinfected patients was associated with a significantly lower risk of diabetes mellitus and possibly chronic...
From the Journals
Initial HCV test results are false positive in almost half of general population
Nearly half of patients in the general population who test positive for hepatitis C virus (HCV) do not have the disease.
From the Journals
VIDEO: Sofosbuvir with velpatasvir beat other HCV GT3 regimens
Regimens containing sofosbuvir and velpatasvir were most effective for treating both cirrhotic and noncirrhotic genotype 3 hepatitis C virus...
From the Journals
Prominent clinical guidelines fall short of conflict of interest standards
Two recent clinical practice guidelines – one for cholesterol management and another for treatment of chronic hepatitis C – did not meet the...
From the Journals
Hepatitis outlook: December 2016
Drug-drug interactions between direct-acting antivirals and antiretroviral therapy are frequently found among HIV/HCV-coinfected patients. Read...
From the Journals
Hepatitis Outlook: November 2016
Baseline hepatitis B core antibody predicts treatment response in chronic HBV patients receiving long-term entecavir, according to a recent study...
From the Journals
Genetics dictate interferon-alfa diarrhea risk
Interferon-alfa impairs human intestinal mucosa homeostasis by eliciting epithelial barrier disruption via apoptosis, and the intestinal mucosa...
Conference Coverage
Sofosbuvir, daclatasvir combo best treatment for HCV cryoglobulinemia vasculitis
The primary endpoint – complete response to treatment at the end of the regimen – was achieved in 91% of subjects by the end of 24 weeks.
From the Journals
Hepatitis Outlook: October 2016
Bonding and linking social capital can be valuable resources in promoting hepatitis C virus treatment uptake and adherence, according to a recent...